Pulmatrix, which recently launched its new iSperse dry powder delivery system, has announced the promotion of Robert Clarke to Chief Scientific Officer (CSO) and VP of Research and Development. In addition, the company has added 8 members to its scientific advisory board.
Clarke has been leading research efforts at Pulmatrix since 2004 after leaving Alkermes. Robert Connelly, President and CEO of Pulmatrix commented, “Bob has been pivotal in the development of our core technologies. In particular, his expertise in respiratory biology and drug delivery are the right combination we need to push our breakthrough technologies forward. We will continue to rely on both his deep scientific insights and strong leadership as we rapidly move through our next stage of growth.”
The new scientific advisory board members include Tony Hickey, Peter Barnes, Richard Ulevitch, Charles Wira, David Clapham, Sanjay Sethi, Mary Fitzgerald, and Richard Boucher. Connelly said, “We are delighted that such a strong group of world-renowned scientific leaders will be joining Pulmatrix’s Scientific Advisory Board to help us advance this novel approach. Our Scientific Advisory Board members are truly ‘hands on’ advisors who are very involved in the key strategies, decisions and often the execution of our iCALM research and formulation plans, clinical trial programs, and Pulmatrix’s drug development programs.”
Read the Pulmatrix press releases on Clarke’s appointment and new advisory board members.
